Summary
Calcium antagonists are potent vasodilators. They improve arterial compliance by their action at the level of the large arteries. Several experimental and clinical studies have shown decreases of varying magnitudes in hypertension-induced cardiac hypertrophy after long term treatment. It appears that the mechanisms of this reduction in cardiac mass are complex. As arterial compliance is one of the determinants of left ventricular hypertrophy in hypertension, it may be considered that an improvement in cardiac mass can result not only from the blood pressure reduction but also from the increase in arterial compliance associated with calcium antagonist treatment in essential sustained hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Asmar RG, Pannier B, Santoni JPh, Laurent St, London GM, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 78: 941–950, 1988
Bouthier JD, De Luca N, Safar ME, Simon ACh. Cardiac hypertrophy and arterial distensibility in essential hypertension. American Heart Journal 109: 1345–1352, 1985
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. American Journal of Cardiology 57: 450–458, 1986
Devereux RB, Pickering TG, Harshfield GA, Kleinen HD, Denby L, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure to regularly recurring stress. Circulation 68: 470–476, 1983
Frishman WH, Skolnick AE, Strom JA. Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy. Circulation 80(Suppl IV): 151–161, 1989
Isnard RN, Pannier BM, Laurent St, London GM, Diebold B, et al. Pulsatile diameter and elastic modulus of the aortic arch in essential hypertension: a non-invasive study. Journal of the American College of Cardiology 13: 399–405, 1989
Levenson JA, Safar ME, Simon ACh, Bouthier JA, Griener L. Central and arterial hemodynamic effects of nifedipine (20mg) in mild to moderate hypertension. Hypertension 5: 57–60, 1983
Levenson JA, Simon ACh, Safar ME, Bouthier J, Maarek BC. Large arteries in hypertension: acute effects of a new calcium entry blocker, nitrendipine. Journal of Cardiovascular Pharmacology 6: S1006–S1010, 1984
Levenson JA, Simon ACh, Safar ME, Bouthier J, Maarek BC. The effect of acute and chronic nicardipine therapy on forearm arterial haemodynamics in essential hypertension. British Journal of Clinical Pharmacology 20: 107S–113S, 1985
Levy BI, Babalis D, La Colly P, Poitevin P, Safar ME. Cardiac hypertrophy and characteristic impedance in spontaneously hypertensive rats. Journal of Hypertension 6(Suppl. N): 5110–5111, 1988
London GM, Marchais SJ, Guerin AP, Metivier F, Safar ME, et al. Salt and water retention and calcium blockade in uremia. Circulation 82: 105–113, 1990b
London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, et al. Aortic and large arteries compliance in end-stage renal failure. Kidney International 37: 137–142, 1990a
Merillon JP, Motte G, Masquet C, Azancot I, Guiomard A, et al. Relationship between physical properties of the arterial system and left ventricular performance in the course of aging and arterial hypertension. European Heart Journal (Suppl. A): 95–102, 1982
Messerli FH, Kaesser UR, Losem CJ. Effects of antihypertensive therapy on hypertensive heart disease. Circulation 80(Suppl. IV): 145–150, 1989
Milnor WR. Hemodynamics, pp. 11–239, Williams & Wilkins, Baltimore, 1982
O’Rourke. Arterial function in health and disease, pp. 3–224, Churchill Livingstone, New York, 1982
Safar ME. Therapeutic trials and large arteries in hypertension. American Heart Journal 115: 702–710, 1988
Safar ME, Pannier BP, Lacolley PJ, Levy BI. Cardiac mass and aortic distensibility following calcium blockade in hypertension. Journal of Cardiovascular Pharmacology 17(Suppl. K): S75–S80, 1991
Safar ME, Simon ACh, Levenson JA, Cazor JL. Hemodynamic effects of diltiazem in hypertension. Circulation Research 52(Suppl. I): 169–173, 1983
Safar ME, Simon ACh, Levenson JA. Structural changes of large arteries in sustained essential hypertension. Hypertension 6(Suppl. III): 117–121, 1984
Schulman SP, Weiss JL, Becker LC, Gottlieb SO, Woodruff KM, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. New England Journal of Medicine 322: 1350–1356, 1990
Tarazi RC. The role of the heart in hypertension. Clinical Science 63 (Suppl.): 347–358, 1982
Thompson SG. Appraisal of the large scale trials of anithypertensive treatment. In Bulpitt CJ (Ed.) Handbook of hypertension, Vol. 6, pp. 331–343, Elsevier Science Publishers, Amsterdam, 1985
Van Merode T, Van Bortel L, Smeets FAM, Böhm R, Mooij J, et al. The effect of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. Journal of Cardiovascular Pharmacology 15: 109–113, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pannier, B.M., Tual, J.L. & Safar, M.E. Cardiac Hypertrophy and Aortic Compliance after Calcium Channel Antagonism in Hypertension. Drugs 44 (Suppl 1), 44–47 (1992). https://doi.org/10.2165/00003495-199200441-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200441-00008